Genprex wins Nasdaq exception to stay listed, must keep shares above $1 through Dec. 7

• Genprex won a Nasdaq hearings panel exception to avoid delisting tied to the $1 minimum bid price rule.
• Compliance required by July 29, 2026; shares must then close at or above $1 each day through Dec. 7, 2026.
• The panel kept jurisdiction through Dec. 7, 2026; it can revisit the exception if events undermine continued listing suitability.
• Genprex implemented a 1-for-22 reverse stock split effective July 16, 2026 to support bid-price compliance.
• The filing flagged Nasdaq’s July 22, 2026 rule change enabling immediate suspension for sub-$5 million market value of listed securities for 30 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025074), on July 30, 2026, and is solely responsible for the information contained therein.